Literature DB >> 26999424

Monoclonal gammopathy-associated pure red cell aplasia.

Neha Korde1,2, Yong Zhang2, Kelsey Loeliger3, Andrea Poon3, Olga Simakova4, Adriana Zingone2, Rene Costello2, Richard Childs3, Pierre Noel5, Samuel Silver6, Mary Kwok7, Clifton Mo7, Neal Young3, Ola Landgren1,2, Elaine Sloand3, Irina Maric5.   

Abstract

Pure red cell aplasia (PRCA) is a rare disorder characterized by inhibition of erythroid precursors in the bone marrow and normochromic, normocytic anaemia with reticulocytopenia. Among 51 PRCA patients, we identified 12 (24%) patients having monoclonal gammopathy, monoclonal gammopathy of undetermined significance or smouldering multiple myeloma, with presence of monoclonal protein or abnormal serum free light chains and atypical bone marrow features of clonal plasmacytosis, hypercellularity and fibrosis. Thus far, three patients treated with anti-myeloma based therapeutics have responded with reticulocyte recovery and clinical transfusion independence, suggesting plasma cells play a key role in the pathogenesis of this specific monoclonal gammopathy-associated PRCA. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  anaemia; monoclonal gammopathy of undetermined significance; myeloma; plasmacytosis; pure red cell aplasia

Mesh:

Substances:

Year:  2016        PMID: 26999424      PMCID: PMC5549779          DOI: 10.1111/bjh.14012

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin.

Authors:  C Peschle; A M Marmont; G Marone; A Genovese; G F Sasso; M Condorelli
Journal:  Br J Haematol       Date:  1975-08       Impact factor: 6.998

Review 2.  Parvovirus B19.

Authors:  Neal S Young; Kevin E Brown
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

3.  The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.

Authors:  S Krüger; M Emig; P Lohse; G Ehninger; A Hochhaus; H K Schackert
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

4.  A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation.

Authors:  J Orchard; H Myint; T J Hamblin
Journal:  Leuk Res       Date:  1997-04       Impact factor: 3.156

5.  Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab.

Authors:  Chi-Chiu So; William W L Choi; Yok-Lam Kwong
Journal:  Ann Hematol       Date:  2013-03-14       Impact factor: 3.673

6.  Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report.

Authors:  Yali Lv; Wenbin Qian
Journal:  Int J Clin Exp Med       Date:  2015-01-15

7.  Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.

Authors:  N Casadevall; E Dupuy; P Molho-Sabatier; G Tobelem; B Varet; P Mayeux
Journal:  N Engl J Med       Date:  1996-03-07       Impact factor: 91.245

8.  Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children.

Authors:  E N Dessypris; S B Krantz; J S Roloff; J N Lukens
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

9.  Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.

Authors:  Ken-ichi Sawada; Makoto Hirokawa; Naohito Fujishima; Masanao Teramura; Masami Bessho; Kazuo Dan; Hisashi Tsurumi; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Keiya Ozawa
Journal:  Haematologica       Date:  2007-07-20       Impact factor: 9.941

10.  Bortezomib to treat the TEMPI syndrome.

Authors:  Mary Kwok; Neha Korde; Ola Landgren
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

View more
  5 in total

1.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

2.  Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone.

Authors:  Abdullah Ladha; Yelena Fudym; Teresa C Gentile
Journal:  J Hematol (Brossard)       Date:  2017-01-10

3.  CB-LPD, MGUS, T-LGLL, and PRCA: A rare case report of 4 concomitant hematological disorders.

Authors:  Qinhong Xu; Jieni Yu; Xiaoyan Lin; Youli Li; Kejie Zhang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

4.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

5.  Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide.

Authors:  Tomoki Ito; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Shosaku Nomura
Journal:  Leuk Res Rep       Date:  2018-07-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.